News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
788,603 Results
Type
Article (73411)
Company Profile (513)
Press Release (714679)
Section
Business (220262)
Career Advice (3284)
Deals (38512)
Drug Delivery (117)
Drug Development (88028)
Employer Resources (182)
FDA (17805)
Job Trends (16637)
News (377766)
Policy (38301)
Tag
Academia (2966)
Alliances (55383)
Alzheimer's disease (1365)
Approvals (17727)
Artificial intelligence (166)
Bankruptcy (383)
Best Places to Work (12470)
Biotechnology (355)
Breast cancer (199)
Cancer (1467)
Cardiovascular disease (126)
Career advice (2772)
CAR-T (109)
Cell therapy (320)
Clinical research (69892)
Collaboration (526)
Compensation (268)
COVID-19 (2813)
C-suite (121)
Data (1428)
Diabetes (190)
Diagnostics (6676)
Earnings (85543)
Employer resources (160)
Events (122670)
Executive appointments (415)
FDA (18511)
Funding (453)
Gene therapy (221)
GLP-1 (716)
Government (4965)
Healthcare (20588)
Infectious disease (2915)
Inflammatory bowel disease (124)
Interviews (607)
IPO (17352)
Job creations (4628)
Job search strategy (2314)
Layoffs (493)
Legal (9540)
Lung cancer (218)
Manufacturing (234)
Medical device (14422)
Medtech (14427)
Mergers & acquisitions (21308)
Metabolic disorders (526)
Neuroscience (1723)
NextGen Class of 2024 (7471)
Non-profit (5036)
Northern California (1735)
Obesity (300)
Opinion (247)
Patents (127)
People (63361)
Phase I (21646)
Phase II (30515)
Phase III (22958)
Pipeline (532)
Postmarket research (3129)
Preclinical (9608)
Radiopharmaceuticals (258)
Rare diseases (291)
Real estate (7013)
Regulatory (25387)
Research institute (2633)
Resumes & cover letters (526)
Southern California (1501)
Startups (4173)
United States (16108)
Vaccines (667)
Weight loss (237)
Date
Today (4)
Last 7 days (635)
Last 30 days (2508)
Last 365 days (37551)
2024 (37364)
2023 (42460)
2022 (53818)
2021 (58599)
2020 (57501)
2019 (50994)
2018 (38856)
2017 (36512)
2016 (37256)
2015 (43341)
2014 (37501)
2013 (33198)
2012 (35212)
2011 (35435)
2010 (34250)
Location
Africa (1117)
Arizona (209)
Asia (47290)
Australia (8037)
California (3989)
Canada (1470)
China (322)
Colorado (182)
Connecticut (196)
Europe (107128)
Florida (550)
Georgia (146)
Illinois (451)
Indiana (240)
Maryland (673)
Massachusetts (3158)
Michigan (190)
Minnesota (313)
New Jersey (1154)
New York (1117)
North Carolina (870)
Northern California (1735)
Ohio (153)
Pennsylvania (950)
South America (1515)
Southern California (1501)
Texas (573)
Utah (116)
Washington State (425)
788,603 Results for "genomma lab internacional s a b de c v".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its First Quarter 2024 Earnings Results on Wednesday, April 24, 2024, after the Mexican Stock Exchange (BMV) close.
April 4, 2024
·
2 min read
Business
Genomma Lab Internacional Announces Results for the First Quarter 2024
Genomma Lab Internacional, S.A.B. de C.V., announced its results for the first quarter of 2024.
April 24, 2024
·
5 min read
Business
Genomma Lab Internacional S.A.B. de C.V. Fourth Quarter and Full Year 2023 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its Fourth Quarter and Full Year 2023 results on Wednesday, February 21, 2024, after the Mexican Stock Exchange (BMV) close.
January 23, 2024
·
2 min read
Genomma Lab Internacional Announces Eighth Dividend Payment
Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.200000 Mexican pesos per share on its common stock representing a total amount of $200,000,000.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on June 21, 2024.
June 13, 2024
·
4 min read
Business
Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the fourth quarter and full year ended December 31, 2023.
February 21, 2024
·
5 min read
Business
Genomma Lab Internacional S.A.B. de C.V. Third Quarter 2023 Earnings Results Conference Call
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”) today announced that it will report its Third Quarter 2023 results on Wednesday, October 25, 2023, after the Mexican Market (BMV) close.
October 4, 2023
·
2 min read
Genomma Lab Internacional Announces Seventh Dividend Payment - March 13, 2024
Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on March 25, 2024.
March 13, 2024
·
3 min read
Policy
Genomma Lab’s ESG Rating Upgraded to A
Genomma Lab Internacional, S.A.B. de C.V. announced that MSCI, one of the world’s largest providers of indices for tracking companies according to environmental, social and governance criteria, upgraded Genomma’s MSCI ESG Rating to A from BBB.
February 28, 2024
·
4 min read
Business
Genomma Lab Internacional Reports Third Quarter 2023 Results
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) (“Genomma Lab” or “the Company”), today announced its results for the third quarter ended September 30, 2023.
October 25, 2023
·
4 min read
Genomma Lab Internacional Announces Sixth Dividend Payment - December 14, 2023
Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of business on December 27, 2023.
December 13, 2023
·
3 min read
1 of 78,861
Next